Brenda Okech
Research Subjects
Brenda Okech has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Ali Ssetaala
Uganda Virus Research Institute—International AIDS Vaccine Initiative (UVRI-IAVI) HIV Vaccine Program Ltd., Entebbe P.O. Box 49, Uganda
4 shared publications Annemarie Namuniina
Affiliation UVRI-IAVI HIV Vaccine Program, Entebbe, Uganda
3 shared publications- Gertrude Nanyonjo
Affiliation UVRI-IAVI HIV Vaccine Program Limited, Entebbe, Uganda
3 shared publications - Aloysious Ssemaganda
Department of National Health Laboratory and Diagnostics Services, Central Public Health Laboratories (NHLDS-CPHL), Ministry of Health, P.O. Box 7272, Kampala, Uganda
2 shared publications - Andrew D. Redd
Division of Intramural Research, NIAID, NIH, Bethesda, MD
2 shared publications Ann Nanteza
Affiliation College of Veterinary Medicine, Animal Resources & Bio-security, Makerere University, Kampala, Uganda
2 shared publications
Latest Publications
- Open Access
- 18 April 2024
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 4 (4) , e0003106
Uptake of Human Papilloma Virus vaccine among young women living in fishing communities in Wakiso and Mukono districts, Uganda
Human Papilloma Virus (HPV) is a preventable cause of cervical cancer, the commonest cancer among women in Uganda. The Uganda Ministry of Health included the HPV vaccine in the free routine immunization schedule since 2015. Five years after this policy, we assessed the uptake of the HPV vaccine and associated socio-demographic factors among young women living in fishing communities in Central Uganda in 2020. We analyzed secondary data from 94 young women aged 9–25 years who were recruited from the two fishing communities (Kasenyi landing site and Koome Island) in a primary study that aimed to promote awareness of maternal and childhood vaccines. We assessed uptake of the HPV vaccine as the proportion of participants who self-reported to have ever received at least one dose of the HPV vaccine. We assessed the socio-demographic factors associated with HPV vaccine uptake using a modified Poisson regression model adjusted for clustering by study site in STATA version 17. The mean (standard deviation) age of study participants was 21.1 (3.1) years and most (81.9%) of them were from Kasenyi landing site. The uptake of the HPV vaccine was 10.6% [95% Confidence Interval (CI) 5.6, 18.9]. After adjusting for covariates, being 13–19 years old (adjusted prevalence ratio [aPR] 5.52, 95%CI 1.69, 18.00) and of Catholic religion (aPR 5.55, 95%CI 1.53, 20.16) were significantly associated with HPV vaccine uptake. The HPV vaccine uptake was very low, despite the reported 99% national coverage of HPV vaccination program for the first dose at the end of 2019. Age and religion showed to be important determinants of the HPV vaccine uptake. Reasons for such very low uptake of HPV vaccinations need to be carefully assessed to find effective strategies to improve it.
- 18 April 2024
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 4 (4) , e0003106
Open AccessUptake of Human Papilloma Virus vaccine among young women living in fishing communities in Wakiso and Mukono districts, Uganda
Human Papilloma Virus (HPV) is a preventable cause of cervical cancer, the commonest cancer among women in Uganda. The Uganda Ministry of Health included the HPV vaccine in the free routine immunization schedule since 2015. Five years after this policy, we assessed the uptake of the HPV vaccine and associated socio-demographic factors among young women living in fishing communities in Central Uganda in 2020. We analyzed secondary data from 94 young women aged 9–25 years who were recruited from the two fishing communities (Kasenyi landing site and Koome Island) in a primary study that aimed to promote awareness of maternal and childhood vaccines. We assessed uptake of the HPV vaccine as the proportion of participants who self-reported to have ever received at least one dose of the HPV vaccine. We assessed the socio-demographic factors associated with HPV vaccine uptake using a modified Poisson regression model adjusted for clustering by study site in STATA version 17. The mean (standard deviation) age of study participants was 21.1 (3.1) years and most (81.9%) of them were from Kasenyi landing site. The uptake of the HPV vaccine was 10.6% [95% Confidence Interval (CI) 5.6, 18.9]. After adjusting for covariates, being 13–19 years old (adjusted prevalence ratio [aPR] 5.52, 95%CI 1.69, 18.00) and of Catholic religion (aPR 5.55, 95%CI 1.53, 20.16) were significantly associated with HPV vaccine uptake. The HPV vaccine uptake was very low, despite the reported 99% national coverage of HPV vaccination program for the first dose at the end of 2019. Age and religion showed to be important determinants of the HPV vaccine uptake. Reasons for such very low uptake of HPV vaccinations need to be carefully assessed to find effective strategies to improve it.
- Open Access
- 17 December 2023
- Published by BMJ in BMJ Global Health
- Vol. 8 (Suppl 10) , A81.2-A82
PA-438 Women’s acceptance and willingness-to-use self-sampling devices for cervical cancer screening in Uganda
Background Cervical cancer is the commonest cancer of women in Uganda. Over 80% of women diagnosed in Mulago a national outpatient and teaching hospital have advanced diseases. Pap smear screening, on an opportunistic rather than systematic basis, is offered free in the gynecological outpatients’ clinic and the postnatal/family planning clinic. One of the objectives of the study was to obtain women’s knowledge, acceptance and willingness to use self-sampling before the development of the cervical cancer screening intervention with a self-sampling device. Methods The study employed a qualitative approach. This was conducted among women and community representatives through Focus Group Discussions. This study was conducted in the districts of Kampala, Mukono, and Wakiso in Uganda to obtain women’s input before starting the development of cervical cancer screening intervention with a self-sampling device. Results The majority of the women expressed positive responses towards a self-sampling device as a very good initiative and were willing to use it if proved effective. Women share perceived benefits as promoting privacy, saving time spent at the clinic, preventing stigma, and solving transport concerns hence promoting cervical cancer screening. Women further preferred self-sampling over standard practices because of no embarrassment and not seem painful. The preferred ways to inform women about the results of self-sampling included designated counselling rooms at health facilities, on the phone if the results are negative, and one-on-one. Conclusion Self-sampling is a crucial initiative and will be welcomed by women however, there is a need to engage, sensitize and involve the target population like policymakers, health workers, politicians, local leaders, policymakers, women leaders (groups), and any other key influential individuals at the community level on the benefits and how to use it before it is rolled out for buy-in.
- 17 December 2023
- Published by BMJ in BMJ Global Health
- Vol. 8 (Suppl 10) , A81.2-A82
Open AccessPA-438 Women’s acceptance and willingness-to-use self-sampling devices for cervical cancer screening in Uganda
Background Cervical cancer is the commonest cancer of women in Uganda. Over 80% of women diagnosed in Mulago a national outpatient and teaching hospital have advanced diseases. Pap smear screening, on an opportunistic rather than systematic basis, is offered free in the gynecological outpatients’ clinic and the postnatal/family planning clinic. One of the objectives of the study was to obtain women’s knowledge, acceptance and willingness to use self-sampling before the development of the cervical cancer screening intervention with a self-sampling device. Methods The study employed a qualitative approach. This was conducted among women and community representatives through Focus Group Discussions. This study was conducted in the districts of Kampala, Mukono, and Wakiso in Uganda to obtain women’s input before starting the development of cervical cancer screening intervention with a self-sampling device. Results The majority of the women expressed positive responses towards a self-sampling device as a very good initiative and were willing to use it if proved effective. Women share perceived benefits as promoting privacy, saving time spent at the clinic, preventing stigma, and solving transport concerns hence promoting cervical cancer screening. Women further preferred self-sampling over standard practices because of no embarrassment and not seem painful. The preferred ways to inform women about the results of self-sampling included designated counselling rooms at health facilities, on the phone if the results are negative, and one-on-one. Conclusion Self-sampling is a crucial initiative and will be welcomed by women however, there is a need to engage, sensitize and involve the target population like policymakers, health workers, politicians, local leaders, policymakers, women leaders (groups), and any other key influential individuals at the community level on the benefits and how to use it before it is rolled out for buy-in.
- Open Access
- 17 December 2023
- Published by BMJ in BMJ Global Health
- Vol. 8 (Suppl 10) , A82.1-A82
PA-441 Establishing an enabling environment for women’s participation in HIV prevention trials among hard-to-reach fishing communities along Lake Victoria Uganda
Background Women are disproportionately affected by HIV/AIDS in Sub-Saharan Africa. Women’s participation in HIV prevention research is associated with men/spousal influence. The willingness of women to participate in HIV prevention research is challenged by negative influences from the male fraternity as primary decision-makers. The UVRI-IAVI HIV Vaccine Program (UVRI-IAVI) engaged both low and high-risk women in HIV vaccine trials and epidemiological preparedness studies. We document experiences of engaging women in HIV prevention research among fishing communities in Uganda. Methods From 2002–2022, Good Participatory Practices (GPP) plans provided a framework of activities that aimed at enhancing male support for women’s participation in research. Community gate keepers and male targeted platforms of engagement were implemented. Women supported disclosure packages, community based male champions of women’s participation, and spousal invitations for HIV risk reduction and appreciation at the research site were conducted. Games and sports activities involving men were organized as advocacy platforms with free treatment extended to spouses and children. Tokens of appreciation benefitting families were offered to female participants at different milestones in studies. Myths and misconceptions surrounding women participation were addressed in communities. Results Between 2002–2022, improved trends in women enrolment and retention were registered when their spouses were involved. Community based structures for male champions promoting advocacy for women participation in research have been established. General community appreciation for women HIV risk and vulnerability assessment form a basis for their consent to women participation in research with emerging trends in adult advocacy for women’s participation in HIV prevention research. Conclusion Advancing women participation in research greatly contributes to the global HIV research efforts for new HIV prevention options.
- 17 December 2023
- Published by BMJ in BMJ Global Health
- Vol. 8 (Suppl 10) , A82.1-A82
Open AccessPA-441 Establishing an enabling environment for women’s participation in HIV prevention trials among hard-to-reach fishing communities along Lake Victoria Uganda
Background Women are disproportionately affected by HIV/AIDS in Sub-Saharan Africa. Women’s participation in HIV prevention research is associated with men/spousal influence. The willingness of women to participate in HIV prevention research is challenged by negative influences from the male fraternity as primary decision-makers. The UVRI-IAVI HIV Vaccine Program (UVRI-IAVI) engaged both low and high-risk women in HIV vaccine trials and epidemiological preparedness studies. We document experiences of engaging women in HIV prevention research among fishing communities in Uganda. Methods From 2002–2022, Good Participatory Practices (GPP) plans provided a framework of activities that aimed at enhancing male support for women’s participation in research. Community gate keepers and male targeted platforms of engagement were implemented. Women supported disclosure packages, community based male champions of women’s participation, and spousal invitations for HIV risk reduction and appreciation at the research site were conducted. Games and sports activities involving men were organized as advocacy platforms with free treatment extended to spouses and children. Tokens of appreciation benefitting families were offered to female participants at different milestones in studies. Myths and misconceptions surrounding women participation were addressed in communities. Results Between 2002–2022, improved trends in women enrolment and retention were registered when their spouses were involved. Community based structures for male champions promoting advocacy for women participation in research have been established. General community appreciation for women HIV risk and vulnerability assessment form a basis for their consent to women participation in research with emerging trends in adult advocacy for women’s participation in HIV prevention research. Conclusion Advancing women participation in research greatly contributes to the global HIV research efforts for new HIV prevention options.
- Open Access
- 16 August 2023
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 3 (8) , e0001566
Proportion of Ugandans with pre-pandemic SARS-CoV-2 cross-reactive CD4+ and CD8+ T-cell responses: A pilot study
The estimated mortality rate of the SARS-CoV-2 pandemic varied greatly around the world. In particular, multiple countries in East, Central, and West Africa had significantly lower rates of COVID-19 related fatalities than many resource-rich nations with significantly earlier wide-spread access to life-saving vaccines. One possible reason for this lower mortality could be the presence of pre-existing cross-reactive immunological responses in these areas of the world. To explore this hypothesis, an exploratory study of stored peripheral blood mononuclear cells (PBMC) from Ugandans collected from 2015–2017 prior to the COVID-19 pandemic (n = 29) and from hospitalized Ugandan COVID-19 patients (n = 3) were examined using flow-cytometry for the presence of pre-existing SARS-CoV-2 cross-reactive CD4+ and CD8+ T-cell populations using four T-cell epitope mega pools. Of pre-pandemic participants, 89.7% (26/29) had either CD4+ or CD8+, or both, SARS-CoV-2 specific T-cell responses. Specifically, CD4+ T-cell reactivity (72.4%) and CD8+ T-cell reactivity (65.5%) were relatively similar, and 13 participants (44.8%) had both types of cross-reactive types of T-cells present. There were no significant differences in response by sex in the population, however this may be in part due to the limited sample size examined. The rates of cross-reactive T-cell populations in this exploratory Ugandan population appears higher than previous estimates from resource-rich countries like the United States (20–50% reactivity). It is unclear what role, if any, this cross-reactivity played in decreasing COVID-19 related mortality in Uganda and other African countries, but does suggest that a better understanding of global pre-existing immunological cross-reactivity could be an informative data of epidemiological intelligence moving forward.
- 16 August 2023
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 3 (8) , e0001566
Open AccessProportion of Ugandans with pre-pandemic SARS-CoV-2 cross-reactive CD4+ and CD8+ T-cell responses: A pilot study
The estimated mortality rate of the SARS-CoV-2 pandemic varied greatly around the world. In particular, multiple countries in East, Central, and West Africa had significantly lower rates of COVID-19 related fatalities than many resource-rich nations with significantly earlier wide-spread access to life-saving vaccines. One possible reason for this lower mortality could be the presence of pre-existing cross-reactive immunological responses in these areas of the world. To explore this hypothesis, an exploratory study of stored peripheral blood mononuclear cells (PBMC) from Ugandans collected from 2015–2017 prior to the COVID-19 pandemic (n = 29) and from hospitalized Ugandan COVID-19 patients (n = 3) were examined using flow-cytometry for the presence of pre-existing SARS-CoV-2 cross-reactive CD4+ and CD8+ T-cell populations using four T-cell epitope mega pools. Of pre-pandemic participants, 89.7% (26/29) had either CD4+ or CD8+, or both, SARS-CoV-2 specific T-cell responses. Specifically, CD4+ T-cell reactivity (72.4%) and CD8+ T-cell reactivity (65.5%) were relatively similar, and 13 participants (44.8%) had both types of cross-reactive types of T-cells present. There were no significant differences in response by sex in the population, however this may be in part due to the limited sample size examined. The rates of cross-reactive T-cell populations in this exploratory Ugandan population appears higher than previous estimates from resource-rich countries like the United States (20–50% reactivity). It is unclear what role, if any, this cross-reactivity played in decreasing COVID-19 related mortality in Uganda and other African countries, but does suggest that a better understanding of global pre-existing immunological cross-reactivity could be an informative data of epidemiological intelligence moving forward.
- Open Access
- 5 July 2023
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 17 (7) , e0011089
Schistosoma mansoni infection alters the host pre-vaccination environment resulting in blunted Hepatitis B vaccination immune responses
Schistosomiasis is a disease caused by parasitic flatworms of the Schistosoma spp., and is increasingly recognized to alter the immune system, and the potential to respond to vaccines. The impact of endemic infections on protective immunity is critical to inform vaccination strategies globally. We assessed the influence of Schistosoma mansoni worm burden on multiple host vaccine-related immune parameters in a Ugandan fishing cohort (n = 75) given three doses of a Hepatitis B (HepB) vaccine at baseline and multiple timepoints post-vaccination. We observed distinct differences in immune responses in instances of higher worm burden, compared to low worm burden or non-infected. Concentrations of pre-vaccination serum schistosome-specific circulating anodic antigen (CAA), linked to worm burden, showed a significant bimodal distribution associated with HepB titers, which was lower in individuals with higher CAA values at month 7 post-vaccination (M7). Comparative chemokine/cytokine responses revealed significant upregulation of CCL19, CXCL9 and CCL17 known to be involved in T cell activation and recruitment, in higher CAA individuals, and CCL17 correlated negatively with HepB titers at month 12 post-vaccination. We show that HepB-specific CD4+ T cell memory responses correlated positively with HepB titers at M7. We further established that those participants with high CAA had significantly lower frequencies of circulating T follicular helper (cTfh) subpopulations pre- and post-vaccination, but higher regulatory T cells (Tregs) post-vaccination, suggesting changes in the immune microenvironment in high CAA could favor Treg recruitment and activation. Additionally, we found that changes in the levels of innate-related cytokines/chemokines CXCL10, IL-1β, and CCL26, involved in driving T helper responses, were associated with increasing CAA concentration. This study provides further insight on pre-vaccination host responses to Schistosoma worm burden which will support our understanding of vaccine responses altered by pathogenic host immune mechanisms and memory function and explain abrogated vaccine responses in communities with endemic infections.
- 5 July 2023
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 17 (7) , e0011089
Open AccessSchistosoma mansoni infection alters the host pre-vaccination environment resulting in blunted Hepatitis B vaccination immune responses
Schistosomiasis is a disease caused by parasitic flatworms of the Schistosoma spp., and is increasingly recognized to alter the immune system, and the potential to respond to vaccines. The impact of endemic infections on protective immunity is critical to inform vaccination strategies globally. We assessed the influence of Schistosoma mansoni worm burden on multiple host vaccine-related immune parameters in a Ugandan fishing cohort (n = 75) given three doses of a Hepatitis B (HepB) vaccine at baseline and multiple timepoints post-vaccination. We observed distinct differences in immune responses in instances of higher worm burden, compared to low worm burden or non-infected. Concentrations of pre-vaccination serum schistosome-specific circulating anodic antigen (CAA), linked to worm burden, showed a significant bimodal distribution associated with HepB titers, which was lower in individuals with higher CAA values at month 7 post-vaccination (M7). Comparative chemokine/cytokine responses revealed significant upregulation of CCL19, CXCL9 and CCL17 known to be involved in T cell activation and recruitment, in higher CAA individuals, and CCL17 correlated negatively with HepB titers at month 12 post-vaccination. We show that HepB-specific CD4+ T cell memory responses correlated positively with HepB titers at M7. We further established that those participants with high CAA had significantly lower frequencies of circulating T follicular helper (cTfh) subpopulations pre- and post-vaccination, but higher regulatory T cells (Tregs) post-vaccination, suggesting changes in the immune microenvironment in high CAA could favor Treg recruitment and activation. Additionally, we found that changes in the levels of innate-related cytokines/chemokines CXCL10, IL-1β, and CCL26, involved in driving T helper responses, were associated with increasing CAA concentration. This study provides further insight on pre-vaccination host responses to Schistosoma worm burden which will support our understanding of vaccine responses altered by pathogenic host immune mechanisms and memory function and explain abrogated vaccine responses in communities with endemic infections.
- Open Access
High proportion of Ugandans with pre-pandemic SARS-CoV-2 cross-reactive CD4+ and CD8+ T-cell responses
The estimated mortality rate of the SARS-CoV-2 pandemic varied greatly around the world with multiple countries in East, Central, and West Africa having significantly lower rates of COVID-19 related fatalities than many resource-rich nations with significantly earlier wide-spread access to life-saving vaccines. One possible reason for this lower mortality could be the presence of pre-existing cross-reactive immunological responses in these areas of the world. To explore this hypothesis, stored peripheral blood mononuclear cells (PBMC) from Ugandans collected from 2015-2017 prior to the COVID-19 pandemic (n=29) and from hospitalized Ugandan COVID-19 patients (n=3) were examined using flow-cytometry for the presence of pre-existing SARS-CoV-2 cross-reactive CD4+ and CD8+ T-cell populations using four T-cell epitope mega pools. Of pre-pandemic participants, 89.7% (26/29) had either CD4+ or CD8+, or both, SARS-CoV-2 specific T-cell responses. Specifically, CD4+ T-cell reactivity (72.4%) and CD8+ T-cell reactivity (65.5%) were relatively similar, and 13 participants (44.8%) had both types of cross-reactive types of T-cells present. There were no significant differences in response by sex in the population. The rates of cross-reactive T-cell populations in these Ugandans is higher than previous estimates from resource-rich countries like the United States (20-50% reactivity). It is unclear what role, if any, this cross-reactivity played in decreasing COVID-19 related mortality in Uganda and other African countries, but does suggest that a better understanding of global pre-existing immunological cross-reactivity could be an informative data of epidemiological intelligence moving forward.
Open AccessHigh proportion of Ugandans with pre-pandemic SARS-CoV-2 cross-reactive CD4+ and CD8+ T-cell responses
The estimated mortality rate of the SARS-CoV-2 pandemic varied greatly around the world with multiple countries in East, Central, and West Africa having significantly lower rates of COVID-19 related fatalities than many resource-rich nations with significantly earlier wide-spread access to life-saving vaccines. One possible reason for this lower mortality could be the presence of pre-existing cross-reactive immunological responses in these areas of the world. To explore this hypothesis, stored peripheral blood mononuclear cells (PBMC) from Ugandans collected from 2015-2017 prior to the COVID-19 pandemic (n=29) and from hospitalized Ugandan COVID-19 patients (n=3) were examined using flow-cytometry for the presence of pre-existing SARS-CoV-2 cross-reactive CD4+ and CD8+ T-cell populations using four T-cell epitope mega pools. Of pre-pandemic participants, 89.7% (26/29) had either CD4+ or CD8+, or both, SARS-CoV-2 specific T-cell responses. Specifically, CD4+ T-cell reactivity (72.4%) and CD8+ T-cell reactivity (65.5%) were relatively similar, and 13 participants (44.8%) had both types of cross-reactive types of T-cells present. There were no significant differences in response by sex in the population. The rates of cross-reactive T-cell populations in these Ugandans is higher than previous estimates from resource-rich countries like the United States (20-50% reactivity). It is unclear what role, if any, this cross-reactivity played in decreasing COVID-19 related mortality in Uganda and other African countries, but does suggest that a better understanding of global pre-existing immunological cross-reactivity could be an informative data of epidemiological intelligence moving forward.